Clinical Advisor

FDA Clears At-Home Neuromodulation Device for Major Depressive Disorder

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under ...

Neurolief receives FDA PMA Approval for First At-Home Brain Neuromodulation Therapy for Adults Whose Depression Was Not Adequately Improved by Antidepres…

Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today ...

Restore Brain Announces Expansion of Neuromodulation Footprint with New St. Louis Office, Bringing Advanced TMS and SPRAVATO Treatments to the Region

With its expansion into St. Louis, Restore Brain continues its mission to broaden access to advanced psychiatric treatments ...
MedPage Today on MSN

FDA approves at-home device for treatment-resistant depression

Prescription neuromodulation can be administered outside the clinic with physician oversig ...
Medical Dialogues

FDA Approves First At-Home Brain Neuromodulation Device for Depression

The FDA has approved ProlivRx, the first prescription, home-based brain neuromodulation therapy, as an adjunctive treatment ...
MassDevice

Neurolief gets FDA approval for at-home neuromod that treats depression

Neurolief announced today that the FDA granted approval for its Proliv Rx at-home neuromodulation therapy for treating ...

First on CNN: Noninvasive brain treatment for depression proves helpful

At Stanford, a treatment that aims magnetic pulses at the brain is showing results for people with treatment-resistant ...
BioWorld

Neuromodulation for MDD heads home

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.
Endovascular Today

CVRx Initiates BENEFIT-HF Trial of Barostim in Expanded Population

CVRx, Inc. a developer of neuromodulation solutions for patients with cardiovascular diseases, announced initiation of the ...
Rutland Herald

Surf Therapeutics Announces Early Feasibility Study (EFS) To Advance Non-Invasive Approach to Neuromodulation for Rheumatoid Arthritis

The clinical trial is expected to enroll up to 40 patients in two stages: an initial open-label pilot (10 patients) followed ...

CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

(NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced ...

Juniper Biomedical Wins Neuromod Prize and Welcomes Frank Fischer to Board of Directors

The Company also announced that Frank Fischer, founder and chairman of the board of Neuropace and medtech serial entrepreneur, recently joined the Juniper Board of Directors.